Antigen in melanoma therapeutic antigen of tumor. Medical search. Frequent questions

In the field of cancer immunotherapy, significant enthusiasm has been directed at the use of cancer vaccines in patients in order to elicit specific immune responses to target tumors. (alphavax.com)
The decision to initiate a cancer immunotherapy program for solid tumors was based on a careful analysis of current cancer therapies and developing strategies. (alphavax.com)
Immunotherapy is emerging as a new form to treat cancer by harnessing the activity of cytotoxic CD8 + T lymphocytes (CTLs) that specifically recognize tumor-associated antigens. (lifeboat.com)
Tumor stem cell-targeted immunotherapy for metastatic melanoma -a randomized phase 3 clinical trial. (ca.gov)
Therapeutic Candidate or Device Tumor stem cell-targeted immunotherapy. (ca.gov)
As the field of cancer immunotherapy advances rapidly, it is now crucial to understand how the dissemination and maintenance of tumor-specific T cells can be optimally achieved. (frontiersin.org)
Valo Therapeutics (Helsinki and Oxford) is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. (helsinki.fi)
The growing trend of implementing immunotherapy into oncology has resulted in a variety of new therapeutic modalities for cancer treatment options, many of which capitalize on the use of antibodies. (news-medical.net)
Immunotherapy is revolutionising the treatment of patients diagnosed with melanoma and other cancers. (biomedcentral.com)
The highly competitive Cancer Research Institute's Clinical Laboratory Integration Program (CRI CLIP) grant will support Verma's lab efforts to improve mitochondrial metabolism in immune cells to make immune checkpoint-based immunotherapy more effective in treating solid tumors. (umn.edu)
However, for now, immunotherapy has a limited efficacy rate of just 20% to 30% when treating patients with solid tumors. (umn.edu)
One of the primary challenges in using immunotherapy to treat solid tumors is that immune cells in solid tumors tend to have dysfunctional mitochondria. (umn.edu)
Several types of ACT round out the immunotherapy arsenal, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapy, and tumor-infiltrating lymphocyte (TIL) therapy. (aacr.org)
Thanks to the power of naturally occurring canine tumors as predictive models for cancer immunotherapy response, these data may represent a basis for the translation of this approach to the treatment of human patients with CSPG4-positive melanoma subtypes. (bmj.com)
Immunotherapy based on the adoptive transfer of ex vivo expanded and activated autologous tumor-reactive lymphocytes can mediate tumor regression in cancer patients. (unimedizin-mainz.de)
We successfully applied this strategy to the human TAAs p53, gp100 and MDM2-specific TCRs as promising antigens-driven immunotherapy for both melanoma and hematologic malignancies. (unimedizin-mainz.de)
Novel immunotherapy strategy and therapeutic target has become a recent research focus in the effort of finding cures for NSCLC. (thno.org)
Tumor immunotherapy brings substantial and long-term clinical benefits that can even cure tumors. (hindawi.com)
Tumor immunotherapy refers to novel therapeutic measures that turn the immune system into a destructive force against tumors [ 1 ]. (hindawi.com)
In recent years, tumor immunotherapy has achieved significant success in various cancers and has been one of the hotspots in the life sciences, especially immune checkpoint inhibitors and adoptive cellular therapy [ 3 ]. (hindawi.com)
We've identified somatic mutations in tumors that are associated with anti-tumor immunity in patients, found T cell subtypes that are associated with a response to anti- PD-1 immunotherapy in melanoma and are studying their properties now (Sade-Feldman et al. (massgeneral.org)
Nat Biotech 2020), which are now being used to develop novel therapeutic approaches and targets for immunotherapy, such as personal tumor vaccines targeting multiple HLA-associated neoantigens in human tumors (together with Dr. Catherine Wu at DFCI, Ott et al. (massgeneral.org)
Furthermore, immunotherapy has revolutionized the management of melanoma, specifically, with inhibition of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), which is expressed on lymphocytes, and programmed death ligand-1, which is expressed on tumor cells. (medscape.com)
Defined immune thresholds for tumor protection and the factors affecting such thresholds have not well been investigated in cancer immunotherapy. (bmj.com)
Including checkpoint inhibitors, the drugs used for immunotherapy, which stimulate the human immune system to attack tumors, are classified as 3rd generation anticancer drugs. (intodeworld.com)
Therefore, advanced technology is needed to increase the therapeutic effect of immunotherapy. (intodeworld.com)
Immunotherapy constitutes an effective treatment for patients with certain types of cancer that have been resistant to chemotherapy and radiation treatment (e.g. melanoma). (edu.au)
Cancer vaccines exploiting the in vivo delivery of tumour specific (neo-)antigens to cross-presenting dendritic cells to improve the immunotherapy for melanoma, breast cancer, lymphoma, glioblastoma and virus-driven tumours. (edu.au)
Identify and validate new classes of tumour antigens that can constitute suitable targets for immunotherapy in various types of cancers. (edu.au)
KEYTRUDA is an immunotherapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. (precisionvaccinations.com)
Anti-cancer vaccination emerged as a promising and cost-effective immunotherapy, but the lack of immunogenicity has hindered the success of therapeutic vaccine development. (ox.ac.uk)

At DFCI, she has initiated an integrated program of research and clinical activities that focuses on dissecting the basis of effective anti-tumor immunity. (nki.nl)
Insight into the mechanisms of anti-tumor immunity has generated great enthusiasm for the treatment of patients with advanced melanoma. (nih.gov)
However, the specific contribution of Trm cells to anti-tumor immunity is incompletely understood. (lifeboat.com)
8-10 Long-lasting protective immunity relies on the efficient establishment of long-lived memory CD8 + T cells, which have the potential to eradicate primary and disseminated tumors. (lifeboat.com)
Therapeutic Mechanism Destruction of host tumor stem cells by adaptive humoral cellular immunity will eradicate the origin of melanoma which will extend patient survival. (ca.gov)
In addition to highlighting key studies that directly implicate T RM cells in anti-tumor immunity, we will highlight earlier work that implicitly suggested their importance. (frontiersin.org)
It was recently reported that LECs suppress the antigen-dependent anti-tumor immunity in cancer tissues. (bvsalud.org)
We have developed genetic and genomics approaches to explain the large variance in anti-tumor immunity across people, and to discover how tumors evolve to resist productive immunity. (massgeneral.org)
In addition, whereas weak pre-existing immunity did not alter the protective thresholds of the vaccine-specific T cell response following subsequent immunization with CMV-based vaccine vectors, strong pre-existing immunity inhibited the development of vaccine-induced T cells and their control on tumor progression. (bmj.com)
Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a critical step in adaptive immunity . (precisionvaccinations.com)
These findings underscore the importance of survivin as a trigger for tumor-restricting immunity and provide therapeutic evidence of ROPs' anti-tumor potential, especially when combined with other immunostimulants, such as anti-4-1BB agonists. (ox.ac.uk)

Cancer can be considered a disease of immune dysfunction, with a failure of immune recognition leading to the outgrowth of malignant cells as tumors ( 1 ). (frontiersin.org)
Gastric cancer (GC) is a common malignant tumor originating from gastric mucosa epithelial cells, and its onset is relatively insidious. (frontiersin.org)
1) Background: T cells are important target cells, since they exert direct cytotoxic effects on infected/malignant cells, and affect the regulatory functions of other immune cells in a target antigen-specific manner. (bvsalud.org)
Patients with oral malignant melanoma often recall having an existing oral pigmentation months to years before diagnosis, and the condition may even have elicited prior comment from examining physicians and dentists (or healthcare providers, when considering the auxiliaries). (medscape.com)
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. (nwbio.com)
More recently, the successes in the treatment of the notoriously refractory malignant melanoma via the targeting of a specific BRAF mutation and via immune activation represent an unprecedented achievement of this new therapeutic direction. (cancernetwork.com)
Malignant melanoma is the most aggressive type of skin cancer, which initiates in the pigment-producing cells called melanocytes. (lu.se)
Our results also show that acquired BRAF-inhibitor (BRAFi) resistance leads to increased expression of HuR and WNT5A in malignant melanoma cells, and simultaneous therapeutic inhibition of HuR function and WNT5A signaling could be an efficient treatment strategy to impair the invasive migration of BRAFi-resistant melanomas. (lu.se)
Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology]. (cdc.gov)

The drug is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma that recurred after initial surgery. (medscape.com)
mRNA-4359 is under development for the treatment of advanced or metastatic solid tumors including cutaneous melanoma, non-muscle invasive bladder cancer, head and neck squamous cell carcinoma, microsatellite stable colorectal cancer (MSS CRC), basal cell carcinoma, triple negative breast cancer and non-small cell lung carcinoma (NSCLC). (pharmaceutical-technology.com)
Oral melanomas are uncommon (1.2 cases per 10 million population per year in the United States), and, similar to their cutaneous counterparts, they are thought to arise primarily from melanocytes in the basal layer of the squamous mucosa. (medscape.com)
In contrast to cutaneous melanomas, which are etiologically linked to sun exposure, risk factors for mucosal melanomas are unknown. (medscape.com)
Approximately 20% of patients with primary cutaneous melanoma will have metastatic melanoma in their SLN. (medscape.com)

Monoclonal antibodies blocking CTLA4 induce regression of immunogenic tumors in mice ( 8 ) and are being pursued as a treatment approach for patients with cancer. (snmjournals.org)
The emerging clinical data suggest that a subset of patients with metastatic melanoma treated with CTLA4-blocking antibodies, in the range of 5%−15%, achieve durable objective tumor responses. (snmjournals.org)
There has been a great deal of interest shown in defining the mechanisms by which anti-CTLA4 antibodies induce tumor regressions in humans. (snmjournals.org)
Please give an overview of the state of immuno-oncological therapeutic antibodies being researched and on the market. (news-medical.net)
Restorative antibodies have accomplished considerable success in treating individuals with haematological BIBX 1382 malignancies and solid tumors. (immune-source.com)
The mechanisms of tumor cell killing by antibodies are summarized as the direct action of the antibody payload delivery and specific effects of an antibody within the tumor vasculature and stroma. (immune-source.com)
While many successful immunotherapeutic regimens have relied on checkpoint inhibition, other immunotherapeutic approaches, such as adoptive cellular therapies (ACT), the use of bispecific antibodies, and targeting components of the tumor microenvironment, are showing promise in a variety of cancer types. (aacr.org)
Recombinant targeting modules will be based on antibodies and soluble single-chain fragments of TCR specific for melanoma antigens. (unimedizin-mainz.de)
Host Response to Tumors The immune response to foreign antigens consists of Humoral mechanisms (eg, antibodies) Cellular mechanisms (See also Tumor Antigens. (msdmanuals.com)

PeptiCRAd uses immunogenic viruses as active carriers of tumour-specific peptides to direct the immune system to specifically target and kill cancer cells. (helsinki.fi)
A total of 139 patients with metastatic melanoma were treated: 54 patients received ipilimumab in conjunction with peptide vaccinations and 85 patients were treated with intra-patient dose escalation of ipilimumab and randomized to receive peptides in accordance with HLA-A*0201 status. (nih.gov)
Conclusion Survivin-specific T-cell reactivities strongly correlate with tumor response and patient survival, indicating that vaccination with survivin-derived peptides is a promising treatment strategy in melanoma. (uni-wuerzburg.de)
A number of in vitro and in vivo studies using bacteriophages expressing other cancer-related antigens or peptides also showed therapeutic effects, indicating that bacteriophage-based anticancer vaccines can be developed as promising immunotherapies. (intodeworld.com)
To address this issue and improve therapeutic efficacy, this study presents the examination of recombinant overlapping peptides (ROP) based on the tumor-associated antigen, survivin, on in vivo immunogenicity and anti-tumor efficacy using a melanoma C57/BL mouse model. (ox.ac.uk)

Transfusion of autologous tumor-specific CTLs 1-4 and blockade of T cell inhibitory receptors 5-7 have demonstrated to elicit durable clinical benefit in a significant proportion of patients with melanoma, leukemia, lymphoma and other cancers, who failed to respond to conventional treatments. (lifeboat.com)
Therapeutic Candidate or Device The therapeutic product candidate is autologous CD34+ hematopoietic stem/progenitor cells (HSPC) transduced with the G1XCGD lentiviral vector. (ca.gov)
Therapeutic Candidate or Device Cryopreserved autologous TRAC locus 1XX BCMA-CAR T cells Indication Relapsed and Refractory Multiple Myeloma Therapeutic Mechanism Engineered T cells target and kill BCMA+ Myeloma cells Unmet Medical Need No durable treatments are available for RRMM and only ~30% of patients can access current BCMA CAR therapies. (ca.gov)
Therapeutic Candidate or Device The therapeutic candidate is a patient specific (autologous) induced pluripotent stem cell derived retinal pigment epithelium (AiPSC-RPE) product. (ca.gov)
In 2010, James Kochenderfer and colleagues achieved a breakthrough with a CAR T cell therapy, reporting tumour regression in a patient with advanced follicular lymphoma, who received two infusions of autologous T cells genetically engineered to express a CAR specifically recognizing the antigen CD19 expressed on B cells. (nature.com)
The therapeutic candidate is administered as an infusion and constitutes autologous T cells genetically engineered to express T-cell receptors (TCR) targeting cancer cells expressing melanoma associated antigen 3 and 6 and is developed based on engineered autologous cell therapy (eACT) platform.It was under development for relapsed and refractory multiple myeloma. (globaldata.com)
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. (nwbio.com)

In a growing number of cases, CD8 T cells have been shown to mediate the regression of large bulky tumors, resulting in durable long-term disease remissions ( 5 ). (frontiersin.org)
Preclinical models predict that blockade of the coinhibitory molecule cytotoxic T lymphocyte-associated antigen 4 (CTLA4) on lymphocytes results in the release of a cell cycle inhibitory checkpoint, allowing lymphocyte proliferation, tumor targeting, and regression. (snmjournals.org)
In 2006, Rosenberg and colleagues transferred TCR T cells specifically recognizing the melanoma antigen MART-1 in 15 patients, two of whom achieved regression and still showed high levels of engineered cells in circulation one year after the infusion. (nature.com)
Reports of spontaneous regression and tumour infiltration with T-lymphocytes makes melanoma candidate for immunotherapies. (mdpi.com)
Tumor-specific T cells are identified, expanded, and infused into the lymphodepleted patient, where they can help mediate tumor regression. (aacr.org)
Interestingly, some recent studies have shown better prognosis and lower rate for positivity of SLN in those patients with regression in their melanoma lesions. (medscape.com)

The mechanism by which vaccine adjuvants enhance immune responses has historically been considered to be the creation of an antigen depot. (mdpi.com)
These posters to be presented at the AACR Meeting focus on the investigational nucleic acid platform, UNITE™ (UNiversal Intracellular Targeted Expression) for two vaccines, ITI-3000 for Merkel cell carcinoma (targeting the large T antigen of the Merkel cell polyomavirus) and Her2/Neu-LAMP DNA vaccine, both of which fuse a tumor associated antigen with lysosomal associated membrane protein 1 (LAMP-1). (biospace.com)
This presentation reports results of pre-clinical mouse studies of a cancer vaccine that promotes potent, antigen-specific CD4 T cell responses to MCPγV-LT. The majority of Merkel cell carcinomas (MCC), a rare and highly aggressive type of neuroendocrine skin cancer, are associated with Merkel cell polyomavirus (MCPyV) infection. (biospace.com)
To activate antigen-specific CD4 T cells in vivo, the investigators utilized the nucleic acid vaccine platform, UNITE (UNiversal Intracellular Targeted Expression), which fuses a tumor-associated antigen with lysosomal-associated membrane protein 1 (LAMP1). (biospace.com)
This presentation reports results of preclinical mouse studies on a HER2/Neu-LAMP DNA vaccine that included a bicistronic DNA construct in which both the tumor antigen (HER2) fused with LAMP-1 (lysosomal- associated membrane protein 1) and sCD40L were expressed separately. (biospace.com)
Chicago - As patient accrual to phase III trials of Canvaxin therapeutic polyvalent cancer vaccine nears the 1,000-mark, a randomized phase II trial of the vaccine was reported at the annual meeting of the American Society of Clinical Oncology. (dermatologytimes.com)
An RNA vaccine that contained this ionizable lipid and an IVT-mRNA encoding a model antigen ovalbumin (OVA) induced OVA-specific cytotoxic T cell responses and showed an antitumor effect against an E.G7-OVA tumor model. (bvsalud.org)
Consistently, the mRNA-LNPs were found to selectively transfect another subset of cDCs, cDC2 that had migrated from the skin to lymph nodes, where they could make vaccine-antigen-dependent contacts with CD8+ T cells. (bvsalud.org)
The therapeutic candidate is an mRNA vaccine. (pharmaceutical-technology.com)
Methods To overcome the host's unresponsiveness to the self-antigen CSPG4, we have taken advantage of the conservation of CSPG4 sequence through phylogenetic evolution, so we have used a vaccine, based on a chimeric DNA molecule encompassing both human (Hu) and dog (Do) portions of CSPG4 (HuDo-CSPG4). (bmj.com)
However, many vaccination trials in melanoma failed to demonstrate a correlation between the vaccine-specific immune response and therapy outcome. (uni-wuerzburg.de)
An mRNA-based cancer vaccine candidate based on BioNTech's FixVac platform, BNT116, contains tumor-linked antigens frequently found in NSCLS. (seekingalpha.com)
Finally, we are adapting our unbiased analytical strategies into real-world therapeutics, having performed clinical trials (with our collaborator Dr. Catherine Wu), in which patients are vaccinated against their own tumors with a fully personal vaccine that is designed based on a computational analysis of their tumor genome. (massgeneral.org)
We here determined using CMV as a vaccine platform whether critical thresholds of vaccine-specific T cell responses can be established that relate to tumor protection, and which factors control such thresholds. (bmj.com)
However, low dose inoculations via the IP or SC route or IN vaccination elicited vaccine-induced CD8 + T cell responses that did not reach protective thresholds for tumor protection. (bmj.com)
Conclusions This study highlight the effectiveness of CMV-based vaccine vectors, and shows that demarcated thresholds of vaccine-specific T cells could be defined that correlate to tumor protection. (bmj.com)
ModernaTX, Inc.'s mRNA novel, personalized cancer vaccine ( PCV ) mRNA-4157 is a therapeutic vaccine candidate combining validated defined neoantigens, predicted neoepitopes, and mutations in driver genes into a single mRNA concatemer ( mRNA-4650 ). (precisionvaccinations.com)
The mRNA personalized cancer vaccine mRNA-4157 is indicated to vaccinate patients with metastatic common epithelial cancers ( melanoma ). (precisionvaccinations.com)
It is an mRNA-based individualized, therapeutic personalized cancer vaccine targeting 20 tumor-associated antigens expressed explicitly by the patient's cancer cells, with potential immunostimulatory and antineoplastic activities. (precisionvaccinations.com)
ROPs and adjuvant immunostimulants represent a potent vaccine strategy for therapeutic purposes, increasing vaccine immunogenicity and improving survival against cancer. (ox.ac.uk)

Emerging evidence indicates that Trm cells develop in human solid cancers and play a key role in controlling tumor growth. (lifeboat.com)

The study demonstrated that specific T cell responses against mutations uniquely harbored in tumor cells can be induced in cancer patients by vaccination. (wikipedia.org)
Particularly, negative regulators of the immune system, called immunologic checkpoints, have been found to play important roles in restraining otherwise effective anti-tumor immunologic responses. (nih.gov)
Moreover, clinically applicable vaccination strategies that efficiently establish Trm cell responses remain largely unexplored and are expected to strongly protect against tumors. (lifeboat.com)
Here we demonstrated that a single intradermal administration of gene- or protein-based vaccines efficiently induces specific Trm cell responses against models of tumor-specific and self-antigens, which accumulated in vaccinated and distant non-vaccinated skin. (lifeboat.com)
Vaccination strategies eliciting CTL responses specific for tumor-specific and self-antigens have shown promising results in recent clinical trials. (lifeboat.com)
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) (also known as CD152) is a major negative regulator of T cell responses which interacts with the B7-1 (CD80) / B7-2 (CD86) ligands on the surface of an antigen-presenting cell. (scielo.br)
CD154) is a transmembrane protein expressed on the surface of activated T cells, particularly on CD4 T cells, which stimulates CD40-dependent activation of antigen-presenting cells (APCs), resulting in enhancement of T cell and antibody responses. (biospace.com)
T RM responses against tumor/self-antigens can concurrently result in the development of pathogenic T RM responses to self, with a growing number of autoimmune diseases and inflammatory pathologies being attributed to T RM responses. (frontiersin.org)
The cytotoxic T lymphocyte-associated antigen 4 (CTLA4) is a coinhibitory activation-induced surface receptor on T cells that functions as a major negative regulator of anti-self-immune responses. (snmjournals.org)
Despite occasional cases of expansion of melanoma-specific T cells ( 14 , 15 ), the bulk of the data suggest that there is no detectable expansion of tumor antigen-specific lymphocytes, in particular when focusing on CD8+ T-cell responses. (snmjournals.org)
Other successful studies quickly followed, such as those demonstrating sustained complete and partial responses in patients with melanoma and treatment of synovial cell sarcoma with TCR T cells against the NY-ESO-1 antigen. (nature.com)
Elucidation of these circadian responses with topical corticosteroids may provide a rational basis for the future re-evaluation of the appropriate therapeutic regimen with this class of drugs in dermatologic medicine. (researchgate.net)
Our findings also revealed that conventional dendritic cells (cDCs) were essential for achieving CD8+ T cell responses induced by the mRNA-LNPs, while the XCR1-positive subset of cDCs, cDC1 specialized for antigen cross-presentation, was not required. (bvsalud.org)
The findings indicate that the activation of innate immune signaling by the adjuvant activity of the vitamin E scaffold and the expression of antigens in cDC2 are important for subsequent antigen presentation and the establishment of antigen-specific immune responses. (bvsalud.org)
However, systematic analysis of T cell immune responses to MAGE-A3 antigen and corresponding antigen-specific TCR is still lacking. (thno.org)
Although immune checkpoint blockade (ICB) reinvigorates anti-tumor immune responses by disrupting co-inhibitory T-cell signaling, relapse frequently occurs after ICB treatment and acquired resistance often emergence after initial response [ 4 ]. (thno.org)
Previously, we showed immune-related adverse events (IRAE) and objective, durable clinical responses in patients with metastatic melanoma treated with CTLA-4 blockade. (nih.gov)
In patients with metastatic melanoma, ipilimumab can induce durable objective clinical responses, which are related to the induction of IRAEs. (nih.gov)
Most humoral responses cannot prevent tumor growth. (msdmanuals.com)
Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. (nwbio.com)
By exploiting the most advanced technologies (nanoparticle-based vaccines, neo-antigens identification and validation, etc.), suitable preclinical models, and investigation of anti-tumour immune responses in cancer patients, we are developing innovative strategies potentially able to improve current approaches. (edu.au)
Tumour neo-antigen-specific immune responses in oesophageal cancer long-term survivors: proof-of-concept for improved personalised therapeutic strategies. (edu.au)
Project aiming at characterizing the role of neo-antigen immune responses in mouse and human breast cancer. (edu.au)
Project aiming at characterising tumour neo-antigen-specific immune responses in oesophageal adenocarcinoma patients with long-term survival. (edu.au)
The data showed that mRNA-4157, combined with Keytruda®, is well tolerated at all dose levels and produced responses measured by tumor shrinkage by RECIST 1.1 criteria in HPV(-) HNSCC patients. (precisionvaccinations.com)

Characterized by cell-surface molecules including CD103, CD69, and CD49a, T RM -like tumor-infiltrating lymphocytes (TILs) can be found in a wide range of human cancers, where they portend improved prognosis. (frontiersin.org)
In these pioneering studies by Steven Rosenberg, tumour-infiltrating lymphocytes (TILs) were isolated from patients with melanoma, then activated and expanded before reinfusion into the patients. (nature.com)
Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. (nwbio.com)
MRP-L28 (39S ribosomal protein L28, melanoma-associated antigen recognized by T lymphocytes) is a mitochondrial protein that belongs to the ribosomal protein L28P family. (thermofisher.cn)

Interestingly, vaccination-induced Trm cells strongly suppress the growth of melanoma, independently of circulating CD8 T cells, and were able to infiltrate melanoma tumors. (lifeboat.com)
Therefore, our work highlights the therapeutic potential of vaccination-induced Trm cells to achieve potent protection against skin malignancies. (lifeboat.com)
Vaccination with LTS220A-UNITE (ITI-3000) induced antigen-specific CD4 Th1 cells that was associated with delayed tumor growth and enhanced survival in treated mice in both the prophylactic and therapeutic settings. (biospace.com)
Vaccination with the LNPs conferred protection against lethal infection by Toxoplasma gondii using its antigen TgPF. (bvsalud.org)
This has prompted us to develop a vaccination strategy employing the tumor antigen chondroitin sulfate proteoglycan (CSPG)4 as a target. (bmj.com)
Conclusions HuDo-CSPG4 adjuvant vaccination was safe and immunogenic in dogs with oral melanoma, with potential beneficial effects on the course of the disease. (bmj.com)
Background Therapeutic vaccination directed to induce an anti-tumoral T-cell response is a field of extensive investigation in the treatment of melanoma. (uni-wuerzburg.de)
This has been mainly attributed to immune escape by antigen loss, rendering us in the need of new vaccination targets. (uni-wuerzburg.de)
Patients and methods This phase-II trial investigated a peptide vaccination against survivin, an oncogenic Background Therapeutic vaccination directed to induce an anti-tumoral T-cell response is a field of extensive investigation in the treatment of melanoma. (uni-wuerzburg.de)
Patients and methods This phase-II trial investigated a peptide vaccination against survivin, an oncogenic inhibitor-of-apoptosis protein crucial for the survival of tumor cells, in HLA-A1/-A2/-B35-positive patients with treatment-refractory stage-IV metastatic melanoma. (uni-wuerzburg.de)
Development and validation of clinically applicable protocols for the identification of tumour-specific immunogenic neo-epitopes to be exploited in personalised vaccination approaches. (edu.au)

She has led early phase clinical trials to test personalized tumor vaccines in melanoma and glioblastoma. (nki.nl)
There are also practical reasons for the attractiveness of therapeutic cancer vaccines-they are easily administered to outpatients and generally do not cause significant side effects. (alphavax.com)
Here, we demonstrated that intradermal administration of clinically relevant vaccines efficiently induces Trm cells specific for tumor-specific and self-antigens that accumulate in vaccinated and non-vaccinated skin. (lifeboat.com)
MCPyV integrates into the host genome, resulting in expression of a truncated form of the viral large T antigen (LT) in infected cells, and makes LT an attractive target for therapeutic cancer vaccines. (biospace.com)
Recent studies in mouse tumor models have shown that T RM cells are induced by cancer vaccines delivered in peripheral tissue sites, or by the depletion of regulatory T cells. (frontiersin.org)
Valo Therapeutics Limited (Valo Tx), an immuno-oncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines, today announced it had received additional funding, triggered by positive pre-clinical data, to progress its PeptiCRAd platform into first-in-human clinical trials. (helsinki.fi)
Michael Stein , CEO of Valo Tx, commented, "With our latest funding from existing investors, of EUR1.1m, we've now raised a total of over EUR 10m, which will enable us to further validate our platform to develop antigen-coated oncolytic viruses as therapeutic vaccines. (helsinki.fi)
Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. (pharmaceutical-technology.com)
The article introduced various studies that investigated the prophylactic and therapeutic effects of anticancer phage-vaccines by utilizing such properties of phages. (intodeworld.com)
In addition, personalized cancer vaccines are designed to prime the immune system so patients can generate a tailored antitumor response specific to their tumor mutation signature. (precisionvaccinations.com)

Jawed vertebrates (gnathostomes) generate a diverse repertoire of B and T cell antigen receptors through the rearrangement of immunoglobulin V, D, and J gene fragments, whereas jawless fish (agnathans) assemble diverse lymphocyte antigen receptor genes through the genomic rearrangement of leucine-rich repeat (LRR) - encoding molecules. (scielo.br)
In melanoma, therapeutic targets include the T cell receptors, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) [ 9 ]. (biomedcentral.com)
They combined the variable region of an antibody with the constant regions of the TCR chains, thus producing chimeric antigen receptors (CARs) that provided T cells with antibody-type specificity. (nature.com)
Chimeric antigen receptors (CAR)-engineered T cells have demonstrated remarkable efficacy in patients with B-cell malignancies. (unimedizin-mainz.de)
Adoptive cell therapy using engineered T-cell receptors (TCRs) targeting cancer-testis antigens, such as Melanoma-associated antigen 3 (MAGE-A3), is a potential approach for the treatment of NSCLC. (thno.org)

He is involved in several ongoing cellular and immuno-gene therapeutic clinical trials and his research group has put major efforts into the development of various T cell-based immunotherapeutic strategies. (wikipedia.org)
Therapies that target these negative regulator checkpoints, such as those directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1), have demonstrated promising clinical results. (nih.gov)
Promising safety and immunogenicity results from the Company's five Phase I clinical studies that evaluated four different alphavaccines, have provided a considerable knowledge base of immunologic information as well as a theoretical framework for immunization against cancer antigens. (alphavax.com)
Funding to support GMP adenovirus manufacture for a First-in-Human basket clinical trial in melanoma, lung cancer, and triple negative breast cancer. (helsinki.fi)
Our first clinical trial will target melanoma, lung cancer and triple negative breast cancer. (helsinki.fi)
Chicago - A phase II trial of a new recombinant agent in the fight against melanoma has accrued 28 patients so far, yielding interesting data but so far no conclusive results, according to an abstract presented at this year's annual meeting of the American Society of Clinical Oncology. (dermatologytimes.com)
We have tested its safety and immunogenicity (primary objectives), along with its therapeutic efficacy (secondary outcome), in a prospective, non-randomized, veterinary clinical trial enrolling 80 client-owned dogs with surgically resected, CSPG4-positive, stage II-IV oral melanoma. (bmj.com)
This paper mainly reviews the clinical features, pathogenesis, and therapeutic strategies of neurologic ir-AEs. (hindawi.com)
Genetic basis for clinical response to CTLA-4 blockade in melanoma. (msdmanuals.com)
Phase 1/2 clinical trials are planned for the therapeutic combination as a first-line option for NSCLC. (seekingalpha.com)
Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK, Fay J. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. (nwbio.com)
Based on early clinical studies, combining mRNA-4157/V940 with KEYTRUDA may provide an additive benefit and enhance T cell-mediated destruction of tumor cells. (precisionvaccinations.com)
On January 9, 2023, the Company confirmed it plans to discuss the study results with regulatory authorities, initiate a Phase 3 clinical study in melanoma patients in 2023, and rapidly expand to additional tumor types. (precisionvaccinations.com)
July 26, 2023 - "As we continue our efforts to advance novel treatment options for patients with high-risk Stage IIB-IV melanoma, the initiation of the V940-001 Phase 3 trial represents an important step forward in these efforts and our study of individualized neoantigen therapy," said Dr. Marjorie Green, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories. (precisionvaccinations.com)

Rosenberg is beginning to develop a library of TCRs that can recognize shared mutations in the hope of utilizing them for TCR T-cell therapy for patients across a variety of tumor types, especially those with common epithelial cancers. (aacr.org)
During the past decade, advancement within the field of genomics has led to the identification of melanoma-specific mutations, namely, v-Raf murine sarcoma viral oncogene homolog B and neuroblastoma RAS viral oncogene homolog, as well as to the development of agents that target these driver mutations. (medscape.com)
Recently, emergence of novel genomic techniques-whole-exome and next-generation sequencing-has enabled the identification of driver mutations in melanoma. (medscape.com)
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin-spurred by the identification of c-Kit-activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec). (cancernetwork.com)
Here, in Part I, we describe areas where major inroads were initially achieved by targeting angiogenesis (central to the biology of renal cell carcinoma and hepatocellular cancer) and by unraveling pathways in the heterogeneous tumors of mesenchymal origin-spurred by the identification of c-Kit-activating mutations in gastrointestinal stromal tumors (GIST) and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec). (cancernetwork.com)
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. (cdc.gov)

These strategies rely on the isolation of T cells, which are either genetically modified to target tumor-specific antigens or are expanded from an endogenous population that recognizes tumor neoantigens. (aacr.org)
Therapeutic response correlates with the mutational load of the patient tumors, suggesting that neoantigens contribute to tumor rejection. (unimedizin-mainz.de)
mRNA-4157/V940 is an investigational messenger ribonucleic acid (mRNA)-based individualized neoantigen therapy consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient's tumor. (precisionvaccinations.com)

The molecular identities of many tumor-associated antigens have been identified and this knowledge has provided a major stimulus for the development of new immunotherapies for the treatment of patients with cancers. (alphavax.com)
Therapeutic Candidate or Device Rebecsinib is a novel small molecule inhibitor of ADAR1 splicing that selectively eradicates therapy-resistant cancer stem cells in blood cancers. (ca.gov)
Brain metastases, as in other systemic cancers, such as lung or breast, remain a significant complication of melanoma. (medscape.com)
For each cancer discussed in the first part of our overview, as well as in Part II, which will deal with more common cancers, we briefly cover the tumor biology, how targeting was achieved, the introduction of immune modulation or immune-conjugates, and the impact these therapies are having in the disease. (cancernetwork.com)
The situation with solid tumors is considerably more complex, and the evolution of targeted therapies for these cancers is still in its infancy. (cancernetwork.com)
In fact, we shall focus on integrating emerging treatments with therapeutic strategies that include both the older endocrine therapies (the "original targeted therapies") against breast and prostate cancers, and the empirically-derived successful chemotherapies, such as platinums, that are used in gynecologic cancers. (cancernetwork.com)

From here, the antigen is slowly released and provided to immune cells over an extended period of time. (mdpi.com)
NK cells coordinate tumor immunosurveillance and the immune response against pathogens. (scielo.br)
Therapeutic Candidate or Device Tissue implant engineered using expanded, allogeneic chondroprogenitor cells Indication Defects of the temporomandibular joint disc complex Therapeutic Mechanism Though the mechanism has not been established, Hyaleon®️ may initially act as a load bearing structure that fills defects of the temporomandibular joint (TMJ) disc complex. (ca.gov)
In addition, ITI-3000 induced changes in the tumor microenvironment, including increased numbers of CD4 and CD8 T cells, reduced frequency of myeloid cells, and enhanced pro-inflammatory cytokine production. (biospace.com)
Such tumor-specific T RM cells are recognized as both necessary and sufficient for long-lived protection against tumors in peripheral tissue locations. (frontiersin.org)
Tumor development has been said to occur in three distinct steps: inefficient elimination of early transformed cells, development of a state of equilibrium between tumor cells and immune cells, and tumor escape from immune pressure ( 2 ). (frontiersin.org)
While innate immune cells are important for early tumor immune surveillance, T cells are fundamentally recognized for their crucial role in the antigen-specific recognition and elimination of malignantly transformed cells ( 2 ). (frontiersin.org)
Following effective priming in lymph nodes, T cells traffic to tumors and other peripheral tissues. (frontiersin.org)
In the early 2000's, large and persistent populations of antigen (Ag)-specific CD8 T cells in peripheral tissues were initially classified as T EM cells in recirculation from the blood ( 8 , 11 ). (frontiersin.org)
It provides a dominant negative signaling to T cells on binding to the costimulatory molecules CD80 (B7.1) and CD86 (B7.2) expressed on the surface of antigen-presenting cells ( 1 ). (snmjournals.org)
Cell surface CTLA4 has 100-1,000 times higher affinity for the costimulatory molecules expressed by antigen-presenting cells, thereby efficiently competing with the positive costimulatory receptor CD28 ( 1 ). (snmjournals.org)
Therapeutics of this nature capitalize on the exquisite specificity of antibody biologics to directly target tumor cells with cytotoxic agents (for example, ADCs) or indirectly target tumor cells by actively recruiting other immune cells (such as T-cells and macrophages) via multi-specific antibody formats. (news-medical.net)
Even more precise targeting is on the horizon: for example, technologies that limit antibody activity to the tumor microenvironment and reduce cytotoxic activity in healthy tissue, resulting in a holistic attack on tumor cells with minimal adverse effects. (news-medical.net)
Compared to traditional chemotherapy, immuno-oncological therapies provide a more indirect attack on tumor cells which generally results in fewer side effects, making the treatment itself more tolerable from a quality of life perspective. (news-medical.net)
In 1989, Zelig Eshhar and colleagues realized that the inability of T cells to recognize surface tumour antigens could be overcome by replacing domains of the T cell receptor (TCR) with antibody parts with specificity towards proteins on these cells. (nature.com)
The T cells expressing CARs recognized and eliminated target cells, and produced interleukin 2 in the presence of the antigen, providing a proof of concept that this approach triggers a cellular immune response. (nature.com)
Physiologic recognition of tumour antigens by T cells is mediated by the TCR-CD3 complex. (nature.com)
Another ACT developed in parallel to CAR T cells is engineering T cells to express TCRs that recognize tumour-associated antigens. (nature.com)
These include the role of host cell PD-L1 expression, efficacy of dual innate and adaptive checkpoints, the role of IFNα targeting, tumor-reprogrammed resident T cells, targeting tertiary lymphoid structures, strategies to facilitate T cell infiltration in tumor microenvironment, and synergistic interactions between radiation and checkpoint blockade. (utsouthwestern.edu)
OncoVEXGM-CSF a recombinant HSV expressing GM-CSF in phase III trial for treatment of melanoma was proved to eliminate malignancy cells by inducing local and systemic antigen-specific T cell reactions and reducing suppressive immune cell populations [12]. (immune-source.com)
CD147 is definitely over-expressed in HCC cells and involved in tumor cell invasion [17] and closely related to prognosis in individuals with HCC [18-22]. (immune-source.com)
The trial used an immunostimulant to enhance the antibody response to a tumor-associated antigen (TA90) found on melanoma cells. (dermatologytimes.com)
Melanoma, the most severe type of skin cancer, arises in melanocytes, the cells that produce melanin in the skin, hair, and eyes. (umn.edu)
Since mitochondria are responsible for providing energy for a cell, this leads to immune cells becoming exhausted by the time they enter the tumor bed, which leaves them unable to effectively fight off cancer cells. (umn.edu)
Through the current CRI-sponsored project, Dr. Verma intends to improve the therapy response in melanoma by preventing mitochondrial exhaustion in immune cells. (umn.edu)
There are many therapeutic avenues that are being tried in clinics against solid tumors that include immune checkpoint inhibitors, adoptive cell therapy and chimeric antigen receptor (CAR) cell therapies, which are all susceptible to failure owing to exhaustion in immune cells," said Dr. Verma. (umn.edu)
Unlike CAR T-cell therapy or TCR therapy, which modifies T cells taken from the blood, TIL therapy utilizes T cells that have infiltrated the tumor stroma, which requires a tumor biopsy. (aacr.org)
To improve this therapeutic strategy, Rosenberg and colleagues developed a method to identify the exact antigens that the T cells could recognize. (aacr.org)
However, high-avidity T cells specific for tumor-associated antigens (TAAs) are usually absent in patients because of self-tolerance. (unimedizin-mainz.de)
Previous work from the contributing DKTK partner sites has demonstrated the versatility of this approach in T cells, and showed that it is feasible to derive CAR-engineered, established human NK cells as an off-the-shelf cellular therapeutic. (unimedizin-mainz.de)
Focusing on advanced melanoma, we will investigate the antitumor activity of UniCAR NK cells in clinically relevant models. (unimedizin-mainz.de)
T cells and TCR will be obtained from blood and tumor tissue and tested for neoantigen specificity and tumor reactivity. (unimedizin-mainz.de)
In this study, we comprehensively screened HLA-A2 restricted MAGE-A3 tumor epitopes and characterized the corresponding TCRs using in vitro artificial antigen presentation cells (APC) system, single-cell transcriptome and TCR V(D)J sequencing, and machine-learning. (thno.org)
Importantly, T cells artificially expressing the MAGE-A3-Mp4 specific TCRs exhibited strong MAGE-A3+ tumor cell recognition and killing effect. (thno.org)
Many tumor cells produce antigens, which may be released in the bloodstream or remain on the cell surface. (msdmanuals.com)
Tumor-associated antigens (TAAs) are relatively restricted to tumor cells. (msdmanuals.com)
Tumor-specific antigens (TSAs) are unique to tumor cells. (msdmanuals.com)
However, several antigens with selective expression on the surface of tumor cells are not associated with the major histocompatibility complex and may be candidates for therapeutic targeting. (msdmanuals.com)
References Many tumor cells produce antigens, which may be released in the bloodstream or remain on the cell surface. (msdmanuals.com)
Recent findings show how T cells exert selection pressures on a tumor, influencing its genetic composition and future susceptibility to the immune system. (massgeneral.org)
Mice were subsequently challenged with tumor cells, and the tumor protection was monitored. (bmj.com)
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. (nwbio.com)
For instance, Pfd8wf phages expressing MAGE (melanoma antigen gene) controlled tumor growth in the mice implanted with melanoma cells, and the overall survival of the mice was extended. (intodeworld.com)
PRAME (Preferentially expressed antigen of melanoma), highly expressed in various solid tumor cells and normal testis, was first isolated as a human melanoma antigen recognized by cytotoxic T cells (CTL). (elsevierpure.com)
Since PRAME was first identified as a tumor antigen recognized by T cells, the possibility that PRAME is a leukemia antigen recognized by T cells was evaluated, and it was found that PRAME-positive leukemia cell lines and fresh leukemia cells were susceptible to lysis by the PRAME-specific CTL. (elsevierpure.com)
As has often been the case, hematologic malignancies have led the way in the introduction of this new generation of therapeutics-perhaps because of easy access to tumor samples for pharmacodynamics, and the narrow spectrum of cells of origin. (cancernetwork.com)
Since analysis of the cytomorphologic features of such nevus cells in the lymph node is so important, it is always recommended to compare these cells with the melanoma cells in the primary lesion. (medscape.com)
Use of IHC to label endothelial cells (CD31, CD34, or D2-40) may be helpful in detecting the rim of endothelial cells, thereby confirming the intravascular location of the cells and supporting a diagnosis of metastatic melanoma. (medscape.com)
Therefore, it is of importance to identify the molecular mechansims that drive metastasis of melanoma cells. (lu.se)
High expression of wingless-type MMTV integration site family 5A (WNT5A) has been reported in melanoma and correlates with increased migration and invasion of melanoma cells. (lu.se)
In this thesis, we investigate that WNT5A and interleukin-6 (IL-6) form a positive feedback loop, which accelerates the invasive property of melanoma cells. (lu.se)
Cellular antigens that are specific for MELANOMA cells. (bvsalud.org)

Her laboratory has focused on the use of genomics-based approaches to discover immunogenic antigen targets and to understand the molecular basis of therapeutic response and resistance. (nki.nl)

Investigators have been enthusiastic about the use of active immunization for patients with solid tumors because of an over-reliance on surrogate and subjective endpoints, such as histologic evidence of tumor necrosis or lymphocyte infiltration, rather than objective cancer regressions. (alphavax.com)

The in-vivo data demonstrated a synergistic improvement in tumour clearance when checkpoint inhibitors were combined with Valo Tx's platform. (helsinki.fi)

The disease is undoubtedly an all natural OV for solid tumor therapy in center trials and displays minimal side-effects with systemic administration [3 4 Lately the toxicity biodistribution and dropping of NDV in nonhuman primates under intravenous shot were examined demonstrating the protection for intravenous administration [5]. (immune-source.com)

Therapeutic Candidate or Device Allogeneic iPSC derived dopamine progenitors delivered to the brain of Parkinson's disease patients Indication Idiopathic Parkinson's disease Therapeutic Mechanism The cellular product reconstitutes dopaminergic neuron circuits lost owing to the disease Unmet Medical Need There are currently disease modifying therapies. (ca.gov)
Adoptive cellular therapy, especially chimeric antigen receptor (CAR) T cell therapy, has gained unprecedented success among hematologic tumors [ 11 ]. (hindawi.com)
In addition to discovering and studying specific molecular and cellular mechanisms, we also address how and why the immune response (to tumors, pathogens or self) varies so dramatically across individuals. (massgeneral.org)

At the end of the 1980s the three-dimensional structure of human leukocyte antigen (HLA) molecule was defined in parallel to identification of tumor-specific gene aberrations. (wikipedia.org)

Molecular imaging with the PET probe 18 F-FLT allows mapping and noninvasive imaging of cell proliferation in secondary lymphoid organs after CTLA4 blockade in patients with metastatic melanoma. (snmjournals.org)
Predicting tumor response to PD-1 blockade. (msdmanuals.com)

Next-generation therapeutics aim to combine the immunotherapeutic benefits of targeting checkpoints in concert with other non-immune chemotherapeutic strategies to provide a targeted assault on the tumor microenvironment. (news-medical.net)

Particularly, we are making a great effort to develop a new immuno-oncology therapy platform by utilizing PHAGERUS ® technology including antigen display and payload technique. (intodeworld.com)

However, although treatment with TILs was effective in some tumours (such as melanoma), the lack of specificity and the difficulty in recruiting TILs from most other cancer types compromised the therapeutic potential. (nature.com)
The UniCAR is only activated upon cross-linking through a soluble tumor-targeting module carrying the UniCAR binding epitope, thereby achieving highest tumor specificity. (unimedizin-mainz.de)
You will find particular proteins with indicated tumor-type specificity: prostate certain antigen in prostate tumors, tyrosinase for melanomas, estrogen receptor protein and foetoprotein for hepatocarcinomas [258]. (estrogen-receptor.com)

The first immune checkpoint inhibitor, ipilimumab (targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)), showed a survival advantage over standard chemotherapy. (biomedcentral.com)
In addition, the advent of immunotherapies, specifically, agents that target cytotoxic T-lymphocyte antigen-4, anti-programmed death-1, and programmed death ligand-1, has increased the potential therapeutic options available to patients with both systemic and brain disease. (medscape.com)

Abstract: Disclosed are therapeutic compounds, protocols, and compositions of matter useful for treatment of neurological conditions. (therapeuticsolutionsint.com)

Therapeutic Candidate or Device HSC gene modified by a lentiviral vector which encodes a triple combination of HIV-resistance genes and a pre-selective marker. (ca.gov)
Background Oncolytic disease which hands the therapeutic gene to improve anti-tumor activity is a common technique to improve oncovirotherapy of tumor. (immune-source.com)
Viral replication and virulence weren't attenuated from the incorporation of cHAb18 gene ICOS which considerably improved the suppression of relict tumor cell migration. (immune-source.com)
Here, we evaluated the safety issues raised by the risk of TAA-TCR gene transfer-associated on/off-target toxicities and the therapeutic potential in relevant transgenic mouse models of adoptive transfer. (unimedizin-mainz.de)
The authors used artificial neural croarrays is to study changes in gene ex- .nature organ the tumor arose from, how big it networks (ANNs) to identify gene-ex- pression that accompany changes in is, and what it looks like after it has pression signatures associated with spe- cell physiology, such as during develop- been imbedded in wax and colored cific subtypes of tumors. (lu.se)

This in turn ruptures the tumors and releases tumor-derived antigens, which, along with GM-CSF, may promote an antitumor immune response. (medscape.com)

Pembrolizumab versus Ipilimumab in Advanced Melanoma. (cancercentrum.se)

In October 2015 the US Food and Drug Administration authorized the injectable formulation of OncoVEXGM-CSF with the brand name Imlygic for the treatment of melanoma in individuals with inoperable tumors. (immune-source.com)

According to most published data, patients in whom the SLN contains metastatic melanoma have a poorer prognosis. (medscape.com)

The field of Lymphocyte Surface Antigens and Activation Mechanisms is examined in two chapters. (scielo.br)

We tested the role of whole-body molecular imaging in patients with advanced melanoma receiving the CTLA4-blocking antibody tremelimumab, allowing the analysis of changes in glucose metabolism using the PET probe 18 F-FDG and cell replication with the PET probe 3′-deoxy-3′- 18 F-fluorothymidine ( 18 F-FLT). (snmjournals.org)
Abveris is a contract research organization specializing in critical reagent and therapeutic antibody discovery for a wide range of targets, including those in the immune-oncology research space. (news-medical.net)
It has been proved to have a beneficial treatment effect on BIBX 1382 prevention of tumor recurrence in individuals with HCC [23 24 We generated a mouse-human chimeric cHAb18 antibody that derived from murine HAb18 and showed inhibition of HCC cell. (immune-source.com)
Pembrolizumab (Keytruda), a humanized monoclonal anti-PD-1 antibody, is the first anti-PD-1 antibody approved by the FDA for the treatment of patients with unresectable or metastatic melanoma, non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, and gastric/gastroesophageal junction cancer [ 4 - 10 ]. (hindawi.com)
In addition, we demonstrate that combined targeting of IL-6 signaling and WNT5A expression, using an anti-IL-6 antibody and a WNT5A antagonist peptide (Box5), respectively, more effectively reduces melanoma cell dissemination, as compared to each factor alone. (lu.se)

Human telomerase reverse transcriptase (hTERT), epithelial development aspect receptor, and survivin are normally active and overexpressed proteins within a variety of tumor types [259]. (estrogen-receptor.com)

Tumors from these patients will be used for peptide ligandome analyses, predictive in-situ biomarker analysis by immunohistochemistry, MALDI-TOF imaging mass spectrometry and RNA sequencing (RNAseq). (unimedizin-mainz.de)
Recent perform elucidated an ultra-selective tumor targeting peptide, v six -BP, that when conjugated to a fluorophore, identified a previously unknown metastatic tumor loci [246], giving evidence that such applications may possibly go beyond therapeutics and involve early detection. (estrogen-receptor.com)

[ 1 ] Because this is typically a late complication of systemic disease, melanoma-related brain metastases have been associated with significant neurologic morbidity and a poor median overall survival, with treatment, of approximately 9 months. (medscape.com)
[ 2 ] Factors that predict survival include age, performance status, and the number of brain metastases, which are summarized as the melanoma-specific graded prognostic assessment. (medscape.com)
Additionally, ROPs significantly reduce tumor size by over 500 mm3 and prolong survival rates in mice with zero deaths in the first 17 days and 30% survival at the end of day 23, while no mice immunized with WT survivin protein survive beyond day 20. (ox.ac.uk)
ROPs combined with anti-4-1BB agonists lead to additional tumor size reduction by 500 mm3 and 70% survival on day 23. (ox.ac.uk)
Early detection of tumors improves survival. (lu.se)

The outcome of the advisory meeting was somewhat of a surprise, as the FDA briefing document released prior to the meeting contained many queries and stated that it was unclear whether the product offers an acceptable benefit-risk profile in a therapeutic field in which many new therapies have recently been launched. (medscape.com)
Melanoma is a skin cancer with permanently increasing incidence and resistance to therapies in advanced stages. (mdpi.com)

Furthermore, the tumor-reactive TCRs with killing potency was screened and verified. (thno.org)
This work identified candidate TCRs potentially suitable for TCR-T design targeting HLA-A2 restricted MAGE-A3 tumor antigen. (thno.org)

The diagnosis is oral melanoma. (medscape.com)
The cause of oral melanoma or melanoma of any mucosal surface remains unknown, and the incidence has remained stable for more than 25 years. (medscape.com)

Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. (cdc.gov)
MCPyV), has been recently identi- real-time RT-PCR assay for detection of fi ed in tumor tissue from patients with 308, and 351 bp, respectively. (cdc.gov)

Due to the unobvious early symptoms and the influence of some adverse factors such as tumor heterogeneity and low immunogenicity, patients with advanced gastric cancer (AGC) cannot benefit significantly from treatments such as radical surgical resection, radiotherapy, chemotherapy, and targeted therapy. (frontiersin.org)
Prof. Nicholas Hayward, Dr. Nic Waddel, Dr. Michele Teng, QIMR-B. Project aiming at characterizing the immunogenicity of acral melanomas. (edu.au)

The Wnt pathway contains quite a few other proteins typically implicated in many types of tumors, particularly inside the stomach and intestines. (estrogen-receptor.com)
An advantage of Moderna's mRNA platform is that it allows for investigational medicines that combine in a single mRNA therapy several different approaches to activate the immune system to attack cancer, either with mRNA encoding for common tumor proteins found across cancer types or multiple mRNAs encoding for various immunomodulatory proteins. (precisionvaccinations.com)

Any molecule capable of being recognized by the immune system is considered an antigen. (msdmanuals.com)
A key role of the immune system is detection of these antigens to permit subsequent targeting for eradication. (msdmanuals.com)

The FDA's approval is based on efficacy data that comes from the OPTiM study , a randomized, controlled trial conducted in adults with unresectable regionally or distantly metastatic melanoma. (medscape.com)

Anatomy21

Organisms9

Diseases39

Chemicals and Drugs112

Analytical, Diagnostic and Therapeutic Techniques and Equipment41

Phenomena and Processes37

Disciplines and Occupations1

Information Science4

Health Care7

Immunotherapy31

Immunity11

Malignant9

Cutaneous5

Antibodies9

Peptides5

Autologous7

Regression6

Vaccine20

Controlling tumor growth1

Responses25

Lymphocytes4

Vaccination11

Vaccines10

Receptors5

Clinical14

Mutations6

Neoantigens3

Cancers6

Cells52

Immunogenic1

Patients with solid tumors1

Checkpoint inhibitors1

Solid tumor1

Cellular3

Human leukocy1

Blockade2

Microenvironment1

Immuno-oncology1

Specificity3

Cytotoxic T-lymphocy2

Abstract1

Gene5

Antitumor1

Ipilimumab1

Treatment of melanoma1

Prognosis1

Mechanisms1

Antibody5

Variety of tumor types1

Peptide2

Survival5

Therapies2

TCRs2

Oral melanoma2

Tissue2

Immunogenicity2

Proteins2

Immune system2

Efficacy1